UPTUNITY Aneurysm AI wins FDA 510(k) clearance for Bracco

Image
UPTUNITY Aneurysm AI wins FDA 510(k) clearance for Bracco

MILAN — November 13, 2026 -- Bracco and Avicenna.AI have received U.S. FDA 510(k) clearance for UPTUNITY | Aneurysm, AI software that flags suspected brain aneurysms larger than 3 mm on head CTA scans. The clearance comes about eight months after the two companies announced their partnership in March 2026.

It is the first product in Bracco's new UPTUNITY portfolio of clinical decision support tools, and the first of the company's AI offerings named in the announcement to interpret images. The existing AiMIFY, developed with Subtle Medical, enhances contrast in brain MRI.

UPTUNITY Aneurysm covers detection and follow-up under two FDA clearances

The product ships under two commercial names: UPTUNITY | Aneurysm Detection (CINA-Aneurysm, K262062) and UPTUNITY | Aneurysm Management (CINA-Aneurysm+, K262147). The detection module is computer-assisted detection and diagnosis software. It acts as a concurrent reading aid and reports the presence, location and size of suspected saccular aneurysms. The management module gives quantitative measurements and compares examinations to track changes over time.

The software does not replace physician review and should not be solely relied upon to make or confirm a diagnosis, according to the release. "The clinical decision stays where it belongs: with the radiologist," said Cosimo DePinto, Executive Vice President, Marketing & Commercial Operations, Bracco Americas.

Avicenna.AI will lead U.S. promotion and distribution of the software

Avicenna.AI, not Bracco, will handle commercial distribution in the United States. Both companies say they are preparing the commercial introduction. The company did not disclose pricing or a launch date.

The target condition is common. The release cites the Brain Aneurysm Foundation's estimate that one in 50 U.S. adults, or 2%, has an unruptured brain aneurysm, and that such aneurysms are often asymptomatic. The release also cites research that aneurysms can be hard to detect on CTA and are often found incidentally during imaging for other reasons. The software is meant to make those findings visible inside the reading workflow radiologists already use.

Bracco ties the launch to its Digital Health strategy and a roughly €180 million R&D budget

Bracco reports consolidated annual revenue of about €2 billion and R&D spending of around 9% of reference turnover. By FairsOnline's calculation, that works out to roughly €180 million a year, assuming reference turnover is close to revenue. Both of Bracco's named AI products, AiMIFY and UPTUNITY, came from outside partners. Fabio Tedoldi, Head of Global Research & Development at Bracco Imaging, says the portfolio extends the company's work beyond contrast agents.

Bracco will show UPTUNITY | Aneurysm at the RSNA 2026 Annual Meeting in Chicago, which runs from November 29 to December 3, 16 days after the clearance announcement.

Published by:
fairsonline_team
Industries